Post-Immunotherapy Axitinib for Patients With Renal Cell Carcinoma

For patients with metastatic renal cell carcinoma (RCC), checkpoint inhibitor therapy is the standard of care. However, if that doesn't work, vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitors can be the next option, but there is no prospective data on the efficacy of these drugs for RCC in this setting. In an attempt to provide evidence for the effectiveness of VEGF-R tyrosine kinase inhibitors for RCC previously treated with immune checkpoint inhibitors, researcher...
Continue reading

JMJD6 Identified as a Neuroblastoma Tumorigenic Factor

Researchers have identified the JMJD6 gene as a critical factor for neuroblastoma tumorigenesis, indicating potential for a new targeted drug therapy treatment strategy. The most prevalent solid tumor in early childhood cancers, neuroblastoma comprises 15% of total childhood cancer deaths. Neuroblastoma is distinctive from adult cancers in that it is characterized by frequent chromosome copy number variations, and its most prominent features are gene deletion, amplification, or gain. While chrom...
Continue reading

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Peter Hillmen, MBChB, PhD

​ For patients experiencing aggressive chronic lymphocytic leukemia (CLL), chemoimmunotherapy often leads to remission, but remission is frequently followed by disease relapse. A new treatment option may soon emerge for these patients: the CLARITY study, a phase 2 clinical trial, has found that the combination of ibrutinib plus venetoclax produces minimal residual disease (MRD)-negative responses in individuals with relapsed and/or refractory CLL, with promising rates of progression-free and ove...
Continue reading

Portable Device Assesses Targeted Therapy’s Effectiveness

​ Researchers have developed a portable system that quickly determines an individual patient's response to targeted cancer therapy. "Our technology combines artificial intelligence and sophisticated biosensors that handle tiny amounts of fluids to see if cancer cells are sensitive or resistant to chemotherapy drugs," commented Mehdi Javanmard, PhD, Assistant Professor of Electrical and Computer Engineering at Rutgers University–New Brunswick and senior author of the study, which has now been pub...
Continue reading

Trastuzumab Duocarmazine in HER2-Positive Cancers

​ A phase 1 clinical trial reports that trastuzumab duocarmazine, a new antibody-drug conjugate that targets human epidermal growth factor receptor 2 (HER2), shows promise in patients with HER2-expressing breast cancer and in HER2-positive advanced and metastatic solid tumors. An antibody-drug conjugate is a type of immunotherapy containing a selective monoclonal antibody, a cytotoxic (cell-killing) agent that causes cell death in the target tumor cell, and a chemical linker that releases the cy...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.